You are here: Home » Markets » News
Business Standard

Pharma shares in focus: Cipla, Aurobindo Pharma hit 52-week high

Dr Reddy's, Divis Labs, Biocon, JB Chemicals, Caplin Point Lab, Aarti Drugs, Indoco Remedies, RPG Lifesciences and Glenmark Pharma were up in the range of 3% to 5%.

Topics
Aurobindo Pharma Cipla | Pharma stocks | Buzzing stocks

SI Reporter  |  Mumbai 

The government is now trying to understand how long it will take before the drug’s production can start in India
The pharma index hit an intra-day high of 9,677, which is 1 per cent short of its 52-week high of 9,753.50 touched on April 27, 2020.

Shares of pharmaceutical companies were in focus on Friday with Nifty Phamra index gaining 2 per cent in an otherwise range-bound market on expectation of strong demand scenario from both domestic and export market.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, May 29 2020. 13:44 IST
RECOMMENDED FOR YOU
.